Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia
Author:
- 27 April 2006
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 12 (s3) , 52-60
Abstract
Summary. The formation of inhibitory alloantibodies is, in the postinfectious era, the most severe and costly complication of replacement therapy in patients with haemophilia. The complexity of the immune response to the infused factor becomes more and more obvious as knowledge in the area increases. Antibodies develop as a result of a complex multi‐factorial interaction between antigen‐presenting cells, T‐ and B‐lymphocytes. Genetic susceptibility of cell surface molecules, such as the major histocompatibility complex, the T‐cell receptor and cytokine receptors, as well as various immunomodulatory molecules have a major impact on the outcome. In addition, environmental factors probably influence the risk of inhibitor development. The current concept of inhibitor development is reviewed. A better understanding of the pathophysiological mechanisms involved will facilitate improvement of therapy in the future, and hopefully provide an opportunity to prevent this complication of treatment.Keywords
This publication has 57 references indexed in Scilit:
- T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjectsJournal of Thrombosis and Haemostasis, 2004
- Epitope repertoire of human CD4 T cells on the A3 domain of coagulation factor VIIIJournal of Thrombosis and Haemostasis, 2004
- Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IXJournal of Thrombosis and Haemostasis, 2004
- Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disordersBlood, 2004
- Recognition of coagulation factor VIII by CD4+ T cells of healthy humansJournal of Thrombosis and Haemostasis, 2003
- Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIIIJournal of Thrombosis and Haemostasis, 2003
- First and Second Generation Recombinant Factor VIII Concentrates in Previously Untreated Patients: Recovery, Safety, Efficacy, and Inhibitor DevelopmentSeminars in Thrombosis and Hemostasis, 2002
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001
- Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titerEuropean Journal of Immunology, 2000
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999